AbbVie not seeking accelerated approval of SCLC candidate

AbbVie Inc. (NYSE:ABBV) said it will not seek accelerated approval from FDA for Rova-T rovalpituzumab tesirine (SC16LD6.5) as third-line treatment of relapsed or refractory small cell lung cancer (SCLC). The company based its decision on the "magnitude of effect across multiple parameters" in the

Read the full 441 word article

User Sign In